Skip to Main content Skip to Navigation
Journal articles

Adverse outcome pathways: opportunities, limitations and open questions

Marcel Leist 1 Ahmed Ghallab 2 Rabea Graepel 3 Rosemarie Marchan 4 Reham Hassan 5 Susanne Hougaard Bennekou 6 Alice Limonciel 7 Mathieu Vinken 8 Stefan Schildknecht 1 Tanja Waldmann 1 Erik Danen 9 Ben van Ravenzwaay 10 Hennicke Kamp 10 Iain Gardner 11 Patricio Godoy 4 Frédéric Bois 12 Albert Braeuning 13 Raymond Reif 4 Franz Oesch 14 Dirk Drasdo 15 Stefan Höhme 16 Michael Schwarz 17 Thomas Hartung 18 Thomas Braunbeck 19 Joost Beltman 9 Harry Vrieling 9 Ferran Sanz 20 Anna Forsby 21 Domenico Gadaleta 22 Ciarán Fisher 21 Jens Kelm 23 David Fluri 23 Gerhard Ecker 24 Barbara Zdrazil 24 Andrea Terron 24 Paul Jennings 25 Bart van der Burg 26 Steven Dooley 27 Annemarie Meijer 9 Egon Willighagen 28 Marvin Martens 28 Chris Evelo 28 Enrico Mombelli 12 Olivier Taboureau 29, 30 Albert Mantovani 31 Barry Hardy 32 Bjorn Koch 9 Sylvia Escher 33 Chris van Thriel 5 Cristina Cadenas 5 D. Kroese 34 Bob van de Water 9 Jan Hengstler 4
15 MAMBA - Modelling and Analysis for Medical and Biological Applications
Inria de Paris, LJLL (UMR_7598) - Laboratoire Jacques-Louis Lions
Abstract : Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a formalized, transparent and quality-controlled way, mechanistic information to apical endpoints for regulatory purposes. AOP links a molecular initiating event (MIE) to the adverse outcome (AO) via key events (KE), in a way specified by key event relationships (KER). Although this approach to formalize mechanistic toxicological information only started in 2010, over 200 AOPs have already been established. At this stage, new requirements arise, such as the need for harmonization and re-assessment, for continuous updating, as well as for alerting about pitfalls, misuses and limits of applicability. In this review, the history of the AOP concept and its most prominent strengths are discussed, including the advantages of a formalized approach, the systematic collection of weight of evidence, the linkage of mechanisms to apical end points, the examination of the plausibility of epidemiological data, the identification of critical knowledge gaps and the design of mechanistic test methods. To prepare the ground for a broadened and appropriate use of AOPs, some widespread misconceptions are explained. Moreover, potential weaknesses and shortcomings of the current AOP rule set are addressed (1) to facilitate the discussion on its further evolution and (2) to better define appropriate vs. less suitable application areas. Exemplary toxicological studies are presented to discuss the linearity assumptions of AOP, the management of event modifiers and compensatory mechanisms, and whether a separation of toxicodynamics from toxicokinetics including metabolism is possible in the framework of pathway plasticity. Suggestions on how to compromise between different needs of AOP stakeholders have been added. A clear definition of open questions and limitations is provided to encourage further progress in the field.
Document type :
Journal articles
Complete list of metadatas

https://hal.inria.fr/hal-01968849
Contributor : Dirk Drasdo <>
Submitted on : Thursday, January 3, 2019 - 1:26:26 PM
Last modification on : Monday, September 28, 2020 - 5:06:50 PM

Links full text

Identifiers

Citation

Marcel Leist, Ahmed Ghallab, Rabea Graepel, Rosemarie Marchan, Reham Hassan, et al.. Adverse outcome pathways: opportunities, limitations and open questions. Archives of Toxicology, Springer Verlag, 2017, 91 (11), pp.3477-3505. ⟨10.1007/s00204-017-2045-3⟩. ⟨hal-01968849⟩

Share

Metrics

Record views

494